Avidity Biosciences Inc (RNA) Stock Price, Quote & News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stag...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 401 7900

Website: www.aviditybiosciences.com

Address:

10578 Science Center Drive, Suite 125, San Diego, United States

CartelCap Dec. 25 at 12:42 PM

$RNA The next leg of valuation movement will likely hinge on how management navigates competing priorities. Competitive dynamics are compressing the timeline for visible traction. Aligned incentives and governance can stabilize expectations. Overall, the trajectory is less about vision and more about proving the operating model works.

0 · Reply

OfficialStocktwitsUser Dec. 25 at 12:01 AM

$RNA RSI: 66.16, MACD: 1.2658 Vol: 0.33, MA20: 71.75, MA50: 67.44 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Power2k Dec. 21 at 1:51 PM

$CAPR $NVS recently acquired $RNA for 12b. Avidity’s del-zota only works for DMD patients with exon44 skipping - a small subset (5-10%) of DMD population. Deramiocel is a Broad mutation-agnostic therapy: Not limited to a specific genetic mutation — can theoretically help all DMD patients, especially for cardiomyopathy, a major cause of death in DMD. Deramiocel is clearly a winner here. Long CAPR for a 9b buyout!

5 · Reply

Diefreeandsell Dec. 19 at 2:18 PM

$CAPR $CDTX $RNA $NVS $VRNA Still above $25? Submission Deadline: During a December 17, 2025 webinar, CEO Linda Marbán stated the company's goal is to send the formal response, including the HOPE-3 topline data, to the FDA before the close of the 2024/2025 calendar year. THIS DECEMBER!!! FDA Feedback: Capricor anticipates receiving feedback from the FDA regarding the "path forward" and the formal acceptance of this filing by the end of January 2026.🤗🤗🥁🥁 Review Period: The resubmission is expected to be treated as a Type 2 classification, which typically carries a six-month review period.✅ Anticipated Approval: Based on this six-month clock, the company is targeting potential FDA approval by mid-2026. 🕰️ When is BO Before or After APPROVAL?🤷‍♂️

2 · Reply

wwmeinc Dec. 18 at 2:17 PM

$RNA Soon...very soon...looking for that date of record. glta https://www.tipranks.com/news/the-fly/avidity-reports-ftc-granted-request-for-early-termination-of-hsr-waiting-period-thefly?mod=mw_quote_news

0 · Reply

Diefreeandsell Dec. 17 at 5:55 PM

$CAPR Bo looks more likely each day it trades above $25. Look at some of the charts & patterns from prev BO co's like $CDTX $RNA $RXDX $VRNA before bo's and analyst rec's. They knew 6 month in advance.

1 · Reply

wwmeinc Dec. 15 at 1:32 AM

$SRPT $RNA ......Very interesting report....~$3B to develop/18 yrs or so....$3.2M cost/vial....~1100 patients treated so far....500 to 600 patients covered my Medicare....price expected to come down in time....less Gov't Reg key but still req'd gov't financial support....all positive....a couple of hiccups but the 60 Minutes program very, very fair...good job...just looking at this with an eye on RNA...glta

1 · Reply

wwmeinc Dec. 12 at 9:43 PM

$RNA .....Guessing somebody got ahold of the 'news' between the RNA HQ and the "SEC" filing office today :) glta https://www.sec.gov/cgi-bin/browse-edgar?company=AVIDITY+BIOSCIENCES&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany "The Company Business evaluated subsequent events to assess the need for potential recognition and disclosure in this report through December 10, 2025, the date on which these condensed combined financial statements were available to be issued. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these condensed combined financial statements, other than those described in Note 1."

0 · Reply

vic_li38 Dec. 4 at 2:32 PM

$RNA push!

0 · Reply

BillionerOfKing Dec. 4 at 10:15 AM

$RNA Current Stock Price: $71.58 Contracts to trade: $70 RNA Dec 19 2025 Call Entry: $1.71 Exit: $2.59 ROI: 51% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Top 2 Health Care Stocks That May Keep You Up At Night In December

HSIC

Nov 20, 2025, 3:45 PM EST - 6 weeks ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH INSM LITE MP

Nov 19, 2025, 9:13 AM EST - 6 weeks ago

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Nov 10, 2025, 4:05 PM EST - 7 weeks ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Oct 28, 2025, 5:13 PM EDT - 2 months ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MRUS MTSR NVS PAGP

Oct 27, 2025, 8:05 PM EDT - 2 months ago

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Oct 27, 2025, 2:52 PM EDT - 2 months ago

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

NVS

Oct 27, 2025, 12:31 PM EDT - 2 months ago

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Oct 27, 2025, 10:22 AM EDT - 2 months ago

Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 8:16 AM EDT - 2 months ago

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

NVS

Oct 27, 2025, 6:54 AM EDT - 2 months ago

Wall Street Breakfast Podcast: Novartis Puts $12B On The Table

HSBC NVS

Oct 27, 2025, 6:29 AM EDT - 2 months ago

Novartis shares slip, Avidity soars after $12 billion biotech deal

NVS

Oct 27, 2025, 4:59 AM EDT - 2 months ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS

Oct 26, 2025, 5:33 PM EDT - 2 months ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

NVS

Oct 26, 2025, 3:46 PM EDT - 2 months ago

Novartis to acquire Avidity Biosciences for about $12B

NVS

Oct 26, 2025, 3:29 PM EDT - 2 months ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS

Oct 26, 2025, 1:07 PM EDT - 2 months ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS

Oct 26, 2025, 1:07 PM EDT - 2 months ago

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

NVS

Oct 26, 2025, 1:00 PM EDT - 2 months ago

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

NVS

Oct 26, 2025, 12:26 PM EDT - 2 months ago

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

NVS

Oct 26, 2025, 11:09 AM EDT - 2 months ago

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

NVS

Oct 16, 2025, 9:00 AM EDT - 2 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Oct 13, 2025, 9:00 AM EDT - 3 months ago

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Oct 6, 2025, 9:00 AM EDT - 3 months ago

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Sep 15, 2025, 4:01 PM EDT - 3 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 11, 2025, 7:56 PM EDT - 4 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Sep 11, 2025, 2:36 PM EDT - 4 months ago

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota

Sep 11, 2025, 8:08 AM EDT - 4 months ago

Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LOVE VERI

Sep 10, 2025, 5:40 PM EDT - 4 months ago

Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)

Sep 10, 2025, 4:01 PM EDT - 4 months ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Sep 10, 2025, 7:00 AM EDT - 4 months ago

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Sep 8, 2025, 4:45 PM EDT - 4 months ago

Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 10:15 PM EDT - 4 months ago

Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:37 AM EDT - 4 months ago

Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 11:41 AM EDT - 5 months ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Jul 28, 2025, 9:00 AM EDT - 5 months ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 23, 2025, 9:00 AM EDT - 5 months ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Jun 11, 2025, 9:00 AM EDT - 7 months ago

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Jun 9, 2025, 7:01 AM EDT - 7 months ago

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Jun 9, 2025, 7:00 AM EDT - 7 months ago

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

May 21, 2025, 4:05 PM EDT - 8 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 4:05 PM EDT - 8 months ago

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

Apr 8, 2025, 9:00 AM EDT - 9 months ago

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Mar 31, 2025, 9:00 AM EDT - 10 months ago

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

CartelCap Dec. 25 at 12:42 PM

0 · Reply

OfficialStocktwitsUser Dec. 25 at 12:01 AM

0 · Reply

Power2k Dec. 21 at 1:51 PM

5 · Reply

Diefreeandsell Dec. 19 at 2:18 PM

2 · Reply

wwmeinc Dec. 18 at 2:17 PM

0 · Reply

Diefreeandsell Dec. 17 at 5:55 PM

1 · Reply

wwmeinc Dec. 15 at 1:32 AM

1 · Reply

wwmeinc Dec. 12 at 9:43 PM

0 · Reply

vic_li38 Dec. 4 at 2:32 PM

$RNA push!

0 · Reply

BillionerOfKing Dec. 4 at 10:15 AM

0 · Reply

wwmeinc Dec. 3 at 6:15 PM

$RNA ......We might be getting close for the Co. to finalize a Date of Record....so far that last SEC filing(Nov.24/25) was just a preliminary release....nothing 'set in stone' in regards to vote,etc...Choice now to sell and move capital elsewhere or hang-tight for the record date and SpinOut news/shares....after the vote of course...glta

0 · Reply

BEATOFtheMARKET Dec. 2 at 4:42 PM

$RLMD $RMBS $RMR $RNA $ROAD Undeniable Accuracy Cycle Trading Signal plugged into AI Lists 🔥

0 · Reply

wwmeinc Dec. 2 at 1:38 AM

$VKTX $IOVA $RNA ....A 'drawback' of receiving an CVR.....courts will now decide if Bristol played 'fast and losse' with the concept....this is why cash is always king...saves any questionable moves by the buyer from coming to bear on shareholders waiting to get paid for a future event...data delay.etc...A promisary note that really is only backed up by the good faith of the issuer.....the courts will decide if this/was the case though...should be an interesting tale though...glta https://www.reuters.com/world/bristol-myers-must-face-67-billion-lawsuit-over-delayed-cancer-drug-us-judge-2025-12-01/

1 · Reply

quickaspeter Nov. 26 at 4:35 PM

$RNA $SRPT $TSHA Amazing…❤️💥🚀💰

0 · Reply

wwmeinc Nov. 26 at 3:25 PM

$VKTX ...For sure.....and with everybody and their mothers and grandparents all looking for that next buy-out candidiate after the great drama PFE/MTSR/NVO gave the mkt/sector....Brian is most likely kicking out the low-ballers as we speak...once they get into office though. What is a bit interesting, is this 'cone of silence' that has dropped on these bidders....Guessing, the lawyers have laid down the law to all employees/bankers/advisors, which in turn shuts out those pesky fin'l reporters looking for the next $RNA scoop...hmmm....just need one...just one to slip under this cone...;) Oh well...just a matter of when not if we get this release...Thanks. glta "In summary, while NVO and LLY currently dominate the market with effective, once-weekly injectable treatments, VKTX is a potential disruptor due to its comparable efficacy data in earlier trials and the potential for a more convenient, less frequent dosing schedule"

2 · Reply

wwmeinc Nov. 25 at 5:54 PM

$RNA ...Noticed how the two Investment bankers/advisors(Barclays and Goldman).....used the WS analysts price targets as a bit of info/data gathering when calculating a 'value' for Sarah/BOD to bring to shareholders....with the final being $72 cash....just saying...and a SpinCo....with its $1.58 handle(pre-listing though)....w/$270M in the bank to boot...that being said...those 350+ pages got to the eyes last night ;) In the end...cash is king, bigtime! Thanks. glta ***Those FT finance reporters....they really deserve all the credit, for my case at least. If I ever looked or had $RNA in one of the watchlists...I cannot remember if I actually ever "re-visited" them before those FT reporters dropped the rumour....still, DD is a requirement...as nothing is guaranteed with biotech's.

0 · Reply

JFais Nov. 25 at 5:07 PM

$RNA $MDGL Congrats on the W @JoseRestonVA Respect the patience & risk mgmt 👏

0 · Reply

dogDazeSummer Nov. 25 at 4:17 PM

Fascinating play by play released SEC filings by and between $RNA and $NVS from July until Ovorvet. Recall the chemo centrix back and forth w $AMGN and realized these deals hinge on 1-2 key attributes. $IFRX $AZN

1 · Reply

dgbio Nov. 25 at 6:36 AM

$RNA Reading merger proxy: • There were several other buyers expressing interest but also saying they need more time. • The deal is done via shareholder vote and not by tender which is faster. • Avidity is able 'in certain circumstances, to furnish information to and conduct negotiations with a third party regarding a bona fide written, unsolicited, alternative Acquisition Proposal (as defined in the section of this proxy statement entitled “The Merger Agreement—Certain Definitions” beginning on page 110) that the Board determines in good faith, after consulting with its outside legal counsel and financial advisors, constitutes or could reasonably be expected to lead to a Superior Proposal'. =>Superior offer remains possible.

0 · Reply

dgbio Nov. 25 at 12:10 AM

$RNA Reading merger proxy: first proposal - $52, second proposal - $60, third proposal - $70, final proposal - $72 + SpinCo. Did a financing because Novartis was conditioning proposal on certain DD results. Said no to this, cut Novartis off the data room and did $500M financing. Boyce is really good. Whatever she does next, I want a share in it.

0 · Reply

Night_Owl_Biotech Nov. 24 at 10:34 PM

@outlawinvestor1 Hey man $RNA filed its 14A today. As you probably know, RNA was acquired for roughly $12B. I have not done the work yet but it appears the enterprise value is roughly $10B (but I need to do the math). Gross margins are forecast to be in the mid-80s (85% at peak). The RNA EV appears to be, more or less, 1X peak sales. I have to leave for the day. I'll compare to the oncology companies tomorrow morning. $XBI $IBB $NBI FYI only.

1 · Reply

wwmeinc Nov. 24 at 5:29 PM

$RNA $TSHA $SRPT This gene news today out of the UK has given the space/sector some good coverage...not company specific per se...charity funding kept the science going in the end...just good/great to see science coming through....glta "In 2020 the university announced a partnership with a small US biotech company Avrobio, to conduct a clinical trial. But three years later the company handed back the licence to the university, following poor results from another gene therapy study and a lack of funds. The first-in-human trial, which would soon help Oliver, was in jeopardy before it had even begun. Prof Jones: "We had to move very quickly to try to save the whole idea and find another sponsor and another source of funding." It was then that British medical research charity, LifeArc, stepped in, providing £2.5m of funding." https://www.bbc.com/news/articles/c5y0y56x6veo

0 · Reply

Market Cap	10.86B
Revenue (ttm)	10.90M
Net Income (ttm)	-322.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,956.88%
Debt to Equity Ratio	0.00

Volume	2,819,444
Avg Vol	5,528,608
Day's Range	N/A - N/A
Shares Out	150.68M
Stochastic %K	18%
Beta	0.95
Analysts	Sell
Price Target	$73.83